Last update 20 Mar 2025

TCRT ESO A2 (Axis Therapeutics Limited)

Overview

Basic Info

Drug Type
TCR-T Cell therapy
Synonyms
TCRTESOA2, TCRTESOA2Axis Therapeutics
Target-
Action-
Mechanism
T lymphocyte replacements
Therapeutic Areas
Neoplasms
Active Indication
Solid tumor
Inactive Indication
Advanced Malignant Solid NeoplasmHead and Neck NeoplasmsHepatocellular Carcinoma+ [3]
Originator Organization
AXISAXIS
Active Organization
Xiangxue Life Science Technology (Guangdong) Co., Ltd.AXISAXIS
Inactive Organization
Athenex, Inc.Athenex, Inc.Xiangxue Pharmaceutical Co., Ltd.Xiangxue Pharmaceutical Co., Ltd.
Drug Highest PhasePreclinical
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with TCRT ESO A2 (Axis Therapeutics Limited)
NCT04878484
/ WithdrawnPhase 1
A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, and Activity of TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
100 Clinical Results associated with TCRT ESO A2 (Axis Therapeutics Limited)
Login to view more data
100 Translational Medicine associated with TCRT ESO A2 (Axis Therapeutics Limited)
Login to view more data
100 Patents (Medical) associated with TCRT ESO A2 (Axis Therapeutics Limited)
Login to view more data
100 Deals associated with TCRT ESO A2 (Axis Therapeutics Limited)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Head and Neck NeoplasmsPhase 3
China
Xiangxue Pharmaceutical Co., Ltd.Xiangxue Pharmaceutical Co., Ltd.
06 Nov 2021
Hepatocellular CarcinomaPhase 3
China
Xiangxue Pharmaceutical Co., Ltd.Xiangxue Pharmaceutical Co., Ltd.
06 Nov 2021
Lung CancerPhase 3
China
Xiangxue Pharmaceutical Co., Ltd.Xiangxue Pharmaceutical Co., Ltd.
06 Nov 2021
SarcomaPhase 3
China
Xiangxue Pharmaceutical Co., Ltd.Xiangxue Pharmaceutical Co., Ltd.
06 Nov 2021
Squamous Cell CarcinomaPhase 3
China
Xiangxue Pharmaceutical Co., Ltd.Xiangxue Pharmaceutical Co., Ltd.
06 Nov 2021
Advanced Malignant Solid NeoplasmPhase 3-
Athenex, Inc.Athenex, Inc.
11 Aug 2021
Solid tumorPhase 3
United States
Athenex, Inc.Athenex, Inc.
-
Solid tumorPreclinical
United States
AXISAXIS
-
Solid tumorPreclinical
China
AXISAXIS
-
Solid tumorPreclinical
United States
Xiangxue Life Science Technology (Guangdong) Co., Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free